384 related articles for article (PubMed ID: 30870525)
1. Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders.
García-Marchena N; Barrera M; Mestre-Pintó JI; Araos P; Serrano A; Pérez-Mañá C; Papaseit E; Fonseca F; Ruiz JJ; Rodríguez de Fonseca F; Farré M; Pavón FJ; Torrens M
PLoS One; 2019; 14(3):e0213791. PubMed ID: 30870525
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder.
Galván ST; Flores-López M; Romero-Sanchiz P; Requena-Ocaña N; Porras-Perales O; Nogueira-Arjona R; Mayoral F; Araos P; Serrano A; Muga R; Pavón FJ; García-Marchena N; de Fonseca FR
Sci Rep; 2021 Jul; 11(1):13629. PubMed ID: 34211033
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity.
Pavón FJ; Araos P; Pastor A; Calado M; Pedraz M; Campos-Cloute R; Ruiz JJ; Serrano A; Blanco E; Rivera P; Suárez J; Romero-Cuevas M; Pujadas M; Vergara-Moragues E; Gornemann I; Torrens M; de la Torre R; Rodríguez de Fonseca F
Addict Biol; 2013 Nov; 18(6):955-69. PubMed ID: 24283982
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of Plasma Growth Factors and Chemokines in Cocaine Use Disorder: Implications for Dual Diagnosis with Schizophrenia and Antisocial Personality Disorder in an Exploratory Study.
Torres-Galván S; Flores-López M; Ochoa E; Requena-Ocaña N; Araos P; Herrera-Imbroda J; Muga R; Serrano A; Rodríguez de Fonseca F; Pavón-Morón FJ; Haro G; García-Marchena N
Neuropsychobiology; 2024; 83(2):73-88. PubMed ID: 38768577
[TBL] [Abstract][Full Text] [Related]
5. Cocaine and depressive disorders: When standard clinical diagnosis is insufficient.
Alías-Ferri M; García-Marchena N; Mestre-Pintó JI; Araos P; Vergara-Moragues E; Fonseca F; González-Saiz F; Rodríguez de Fonseca F; Torrens M; Group N
Adicciones; 2021 Jul; 33(3):193-200. PubMed ID: 32100040
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of plasma cytokines in patients with cocaine use disorders in abstinence identifies transforming growth factor alpha (TGFα) as a potential biomarker of consumption and dual diagnosis.
Maza-Quiroga R; García-Marchena N; Romero-Sanchiz P; Barrios V; Pedraz M; Serrano A; Nogueira-Arjona R; Ruiz JJ; Soria M; Campos R; Chowen JA; Argente J; Torrens M; López-Gallardo M; Marco EM; Rodríguez de Fonseca F; Pavón FJ; Araos P
PeerJ; 2017; 5():e3926. PubMed ID: 29038767
[TBL] [Abstract][Full Text] [Related]
7. Plasma Chemokines in Patients with Alcohol Use Disorders: Association of CCL11 (Eotaxin-1) with Psychiatric Comorbidity.
García-Marchena N; Araos PF; Barrios V; Sánchez-Marín L; Chowen JA; Pedraz M; Castilla-Ortega E; Romero-Sanchiz P; Ponce G; Gavito AL; Decara J; Silva D; Torrens M; Argente J; Rubio G; Serrano A; de Fonseca FR; Pavón FJ
Front Psychiatry; 2016; 7():214. PubMed ID: 28149283
[TBL] [Abstract][Full Text] [Related]
8. Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity.
Araos P; Pedraz M; Serrano A; Lucena M; Barrios V; García-Marchena N; Campos-Cloute R; Ruiz JJ; Romero P; Suárez J; Baixeras E; de la Torre R; Montesinos J; Guerri C; Rodríguez-Arias M; Miñarro J; Martínez-Riera R; Torrens M; Chowen JA; Argente J; Mason BJ; Pavón FJ; Rodríguez de Fonseca F
Addict Biol; 2015 Jul; 20(4):756-72. PubMed ID: 24854157
[TBL] [Abstract][Full Text] [Related]
9. Independent versus substance-induced major depressive disorder in substance-dependent patients: observational study of course during follow-up.
Nunes EV; Liu X; Samet S; Matseoane K; Hasin D
J Clin Psychiatry; 2006 Oct; 67(10):1561-7. PubMed ID: 17107247
[TBL] [Abstract][Full Text] [Related]
10. BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression.
Fonseca F; Mestre-Pinto JI; Rodríguez-Minguela R; Papaseit E; Pérez-Mañá C; Langohr K; Barbuti M; Farré M; Torrens M;
Front Psychiatry; 2022; 13():836771. PubMed ID: 35370811
[TBL] [Abstract][Full Text] [Related]
11. Plasma concentrations of BDNF and IGF-1 in abstinent cocaine users with high prevalence of substance use disorders: relationship to psychiatric comorbidity.
Pedraz M; Martín-Velasco AI; García-Marchena N; Araos P; Serrano A; Romero-Sanchiz P; Suárez J; Castilla-Ortega E; Barrios V; Campos-Cloute R; Ruiz JJ; Torrens M; Chowen JA; Argente J; de la Torre R; Santín LJ; Villanúa MÁ; Rodríguez de Fonseca F; Pavón FJ
PLoS One; 2015; 10(3):e0118610. PubMed ID: 25734326
[TBL] [Abstract][Full Text] [Related]
12. Comorbidity of Lifetime Alcohol Use Disorder and Major Depressive Disorder in San Juan, Puerto Rico.
Caetano R; Vaeth PAC; Canino G
J Stud Alcohol Drugs; 2019 Sep; 80(5):546-551. PubMed ID: 31603756
[TBL] [Abstract][Full Text] [Related]
13. The bidirectional relationships between alcohol, cannabis, co-occurring alcohol and cannabis use disorders with major depressive disorder: results from a national sample.
Pacek LR; Martins SS; Crum RM
J Affect Disord; 2013 Jun; 148(2-3):188-95. PubMed ID: 23260381
[TBL] [Abstract][Full Text] [Related]
14. Depressed patients with co-occurring alcohol use disorders: a unique patient population.
Sher L; Stanley BH; Harkavy-Friedman JM; Carballo JJ; Arendt M; Brent DA; Sperling D; Lizardi D; Mann JJ; Oquendo MA
J Clin Psychiatry; 2008 Jun; 69(6):907-15. PubMed ID: 18422397
[TBL] [Abstract][Full Text] [Related]
15. The Tryptophan System in Cocaine-Induced Depression.
Fonseca F; Mestre-Pintó JI; Gómez-Gómez À; Martinez-Sanvisens D; Rodríguez-Minguela R; Papaseit E; Pérez-Mañá C; Langohr K; Valverde O; Pozo ÓJ; Farré M; Torrens M; On Behalf Of Neurodep Group
J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33352710
[TBL] [Abstract][Full Text] [Related]
16. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I
Keller B; Mestre-Pinto JI; Álvaro-Bartolomé M; Martinez-Sanvisens D; Farre M; García-Fuster MJ; García-Sevilla JA; Torrens M;
Front Psychiatry; 2017; 8():258. PubMed ID: 29326609
[TBL] [Abstract][Full Text] [Related]
17. Medical complications associated with substance use disorders in patients with type 2 diabetes and hypertension: electronic health record findings.
Winhusen T; Theobald J; Kaelber DC; Lewis D
Addiction; 2019 Aug; 114(8):1462-1470. PubMed ID: 30851217
[TBL] [Abstract][Full Text] [Related]
18. Personality traits in substance use disorders and obesity when compared to healthy controls.
Ramirez V; Wiers CE; Wang GJ; Volkow ND
Addiction; 2020 Nov; 115(11):2130-2139. PubMed ID: 32350970
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample.
Peer K; Rennert L; Lynch KG; Farrer L; Gelernter J; Kranzler HR
Drug Alcohol Depend; 2013 Jan; 127(1-3):215-9. PubMed ID: 22884164
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic sequence of cocaine use disorder in relation to other mental health conditions among college students.
Liu Y; Ball JD; Elliott AL; Jacobs-Elliott M; Nicolette G
J Am Coll Health; 2020; 68(6):575-578. PubMed ID: 30908134
[No Abstract] [Full Text] [Related]
[Next] [New Search]
